2022
Cathepsin B p.Gly284Val Variant in Parkinson's Disease Pathogenesis
MILANOWSKI, Lukasz M, Xu HOU, Jenny M BREDENBERG, Fabienne C FIESEL, Liam T COCKER et. al.Základní údaje
Originální název
Cathepsin B p.Gly284Val Variant in Parkinson's Disease Pathogenesis
Autoři
MILANOWSKI, Lukasz M, Xu HOU, Jenny M BREDENBERG, Fabienne C FIESEL, Liam T COCKER, Alexandra I SOTO-BEASLEY, Ronald L WALTON, Audrey J STRONGOSKY, Ayman H FAROQI, Maria BARCIKOWSKA, Magdalena BOCZARSKA-JEDYNAK, Jaroslaw DULSKI, Lyuda FEDORYSHYN, Piotr JANIK, Anna POTULSKA-CHROMIK, Katherine KARPINSKY, Anna KRYGOWSKA-WAJS, Tim LYNCH, Diana A OLSZEWSKA, Grzegorz OPALA, Aleksander PULYK, Irena REKTOROVÁ (203 Česká republika, garant, domácí), Yanosh SANOTSKY, Joanna SIUDA, Mariusz WIDLAK, Jaroslaw SLAWEK, Monika RUDZINSKA-BAR, Ryan UITTI, Monika FIGURA, Stanislaw SZLUFIK, Sylwia RZONCA-NIEWCZAS, Elzbieta PODGORSKA, Pamela J MCLEAN, Dariusz KOZIOROWSKI, Owen A ROSS, Dorota HOFFMAN-ZACHARSKA, Wolfdieter SPRINGER a Zbigniew K WSZOLEK
Vydání
International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2022, 1422-0067
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10608 Biochemistry and molecular biology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.600
Kód RIV
RIV/00216224:14740/22:00127440
Organizační jednotka
Středoevropský technologický institut
UT WoS
000824355700001
Klíčová slova anglicky
Parkinson's disease; familial forms; monogenic forms; CTSB; fibroblasts
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 3. 4. 2023 10:10, Mgr. Pavla Foltynová, Ph.D.
Anotace
V originále
Parkinson's disease (PD) is generally considered a sporadic disorder, but a strong genetic background is often found. The aim of this study was to identify the underlying genetic cause of PD in two affected siblings and to subsequently assess the role of mutations in Cathepsin B (CTSB) in susceptibility to PD. A typical PD family was identified and whole-exome sequencing was performed in two affected siblings. Variants of interest were validated using Sanger sequencing. CTSB p.Gly284Val was genotyped in 2077 PD patients and 615 unrelated healthy controls from the Czech Republic, Ireland, Poland, Ukraine, and the USA. The gene burden analysis was conducted for the CTSB gene in an additional 769 PD probands from Mayo Clinic Florida familial PD cohort. CTSB expression and activity in patient-derived fibroblasts and controls were evaluated by qRT-PCR, western blot, immunocytochemistry, and enzymatic assay. The CTSB p.Gly284Val candidate variant was only identified in affected family members. Functional analysis of CTSB patient-derived fibroblasts under basal conditions did not reveal overt changes in endogenous expression, subcellular localization, or enzymatic activity in the heterozygous carrier of the CTSB variant. The identification of the CTSB p.Gly284Val may support the hypothesis that the CTSB locus harbors variants with differing penetrance that can determine the disease risk.